Substance and claimed effects

The Anti-Inflammatory Reliever (AIR) and Maintenance-and-Reliever Therapy (MART) regimens are the Global Initiative for Asthma's Track 1 preferred treatment pathway for adolescents and adults with asthma GINA 2024. Both use a single combination inhaler containing a low-dose inhaled corticosteroid (ICS) — typically budesonide — combined with formoterol, a long-acting beta-2 agonist (LABA) with onset of action within 1–3 minutes that is fast enough to also function as a rescue bronchodilator. AIR uses the combination inhaler only as needed for symptoms (Steps 1–2; mild asthma); MART uses the same inhaler as a daily maintenance dose plus additional as-needed doses for symptoms (Steps 3–5; moderate-to-severe asthma). The replaced practice — short-acting beta-agonist (SABA, e.g. salbutamol/albuterol) used alone for reliever, with or without a separate ICS maintenance inhaler — is the comparator throughout. The substance produces effects across symptom control, severe exacerbation rate, oral corticosteroid (OCS) exposure, nocturnal sleep disruption, exercise tolerance, adherence behaviour, and downstream OCS-related morbidity (osteoporosis, cataract, diabetes, weight gain). The 2019 GINA strategy revision was the largest shift in asthma management in three decades; SABA-only reliever therapy is no longer recommended at any step Reddel et al. 2019.

Evidence by addressing question

Mechanism

Asthma is a chronic inflammatory airway disease, not primarily a bronchospasm disease. The dominant lesion is eosinophilic and T-helper-2 driven mucosal inflammation, with secondary smooth-muscle hyperreactivity and mucus hypersecretion. A SABA (salbutamol, terbutaline) acts on beta-2 receptors on bronchial smooth muscle, producing bronchodilation within ~5 minutes lasting ~4–6 hours — but does nothing to the underlying inflammation. It relieves the felt symptom without treating the disease. Repeated SABA-only use can in fact worsen disease through beta-receptor downregulation, increased bronchial hyperresponsiveness, and possibly increased eosinophilic inflammation Reddel et al. 2019.

An ICS (budesonide, beclomethasone, fluticasone) suppresses airway inflammation by binding glucocorticoid receptors in airway epithelial and immune cells, reducing eosinophilic infiltration, mucus production, and bronchial hyperreactivity. The pharmacological insight underpinning AIR/MART: people reach for a reliever when they have symptoms, which is precisely the moment airway inflammation is flaring. Coupling an ICS dose to every reliever event delivers anti-inflammatory therapy exactly when it's needed — and titrates ICS dose automatically to disease activity. Formoterol is the unique LABA suitable for this role because, unlike salmeterol, it has fast onset (~1–3 min) comparable to a SABA, while retaining ~12-hour duration. The fixed-dose combination prevents LABA monotherapy (which is unsafe in asthma) by making the ICS unavoidable on every reliever use GINA 2024.

Evidence

The pivotal trials for the AIR approach in mild asthma are SYGMA 1 and SYGMA 2. SYGMA 1 (n=3,849) was a 52-week double-blind RCT randomising patients with mild asthma to as-needed terbutaline (SABA-only), as-needed budesonide–formoterol (BUD-FORM), or twice-daily maintenance budesonide plus as-needed terbutaline. As-needed BUD-FORM was superior to as-needed SABA for severe exacerbations (rate ratio 0.36, 64% reduction) and non-inferior to maintenance budesonide, while delivering only 17% of the inhaled steroid dose of the maintenance arm O'Byrne et al. 2018. SYGMA 2 (n=4,215) was the open-label real-world companion: as-needed BUD-FORM was non-inferior to maintenance budesonide for severe exacerbation rate (0.11 vs 0.12/year), again at a fraction of the steroid load Bateman et al. 2018.

Two independent open-label trials replicated the finding. Novel START (n=668, New Zealand) compared as-needed BUD-FORM, as-needed albuterol, and maintenance budesonide plus as-needed albuterol over 52 weeks; as-needed BUD-FORM produced a 51% lower rate of severe exacerbations than as-needed albuterol and was similar to maintenance budesonide Beasley et al. 2019. PRACTICAL (n=890, also New Zealand) compared as-needed BUD-FORM against the then-standard of maintenance budesonide plus as-needed terbutaline; the BUD-FORM arm had a 31% lower severe exacerbation rate (RR 0.69) — the first trial to show superiority of an AIR regimen over a maintenance-ICS+SABA regimen for exacerbations Hardy et al. 2019.

For the MART pathway (moderate-to-severe asthma), the evidence base is older and larger. A Cochrane review pooled 16 trials (n≈22,500) and found MART reduced severe exacerbations requiring hospitalisation or oral steroids compared to fixed-dose ICS-LABA plus SABA (odds ratio 0.72) and compared to higher-dose ICS plus SABA Cates and Karner 2013. A 2018 network meta-analysis in JAMA covering 16,857 patients confirmed MART was the most effective regimen for reducing exacerbations across persistent asthma severity tiers Sobieraj et al. 2018.

The harm side of the SABA-only comparator is anchored by two epochs of evidence. The 1992 case-control study of the New Zealand fenoterol mortality epidemic found that monthly SABA canister use was associated with a stepwise increase in asthma death — odds ratio approximately 2.0 per canister/month Spitzer et al. 1992. The modern replication is the SABINA II programme: in a nationwide Swedish cohort of 365,324 asthma patients, dispensing of ≥3 SABA canisters/year (≈1+ canister/month) was associated with a 26% increased exacerbation rate and a 26% increased all-cause mortality versus 0–2 canisters/year, with a clear dose-response across canister bands Nwaru et al. 2020. Approximately one-third of asthma patients in Western health systems meet the ≥3 canisters/year overuse threshold.

Protocol

The standard AIR/MART preparation is budesonide 160–200 µg / formoterol 4.5–6 µg per actuation (the "Symbicort 200/6" or generic equivalent). Beclomethasone–formoterol is licensed equivalently in some jurisdictions. AIR (Steps 1–2): one inhalation as needed for symptoms; no scheduled maintenance dose. MART (Steps 3–5): one inhalation twice daily as scheduled maintenance, plus one inhalation as needed for symptoms, up to a maximum of approximately 12 inhalations/day. The salbutamol/albuterol rescue inhaler is withdrawn from the prescription on Track 1 — a deliberate behavioural change GINA 2024.

Contraindications

Asthma is itself a setting where the regimen is recommended in pregnancy — uncontrolled asthma is more dangerous to the fetus than budesonide exposure. Formoterol shares LABA-class cautions for unstable cardiac arrhythmia and uncontrolled hypertension; clinically these rarely override the indication. The historical LABA-monotherapy safety signal (Salmeterol Multicenter Asthma Research Trial, 2006) drove the FDA black-box warning that does not apply to fixed-dose ICS-LABA combinations such as those used in AIR/MART GINA 2024.

Misconceptions

The dominant misconception, held by clinicians as well as patients, is that the reliever inhaler is the "safe" inhaler and the steroid inhaler is the "scary" one. The data inverts that intuition: it is precisely the patient who relies heavily on a reliever and skips the controller who is at highest risk of exacerbation and death Nwaru et al. 2020. A second misconception is that as-needed ICS-formoterol is "just a reliever with a little steroid" — in mild asthma it is actually superior to many maintenance-only regimens for exacerbation prevention Hardy et al. 2019. A third: that more SABA is the appropriate response to worsening symptoms. SABA escalation in the absence of ICS escalation is the canonical death-spiral pattern in fatal asthma case series.

Failure modes

Adherence to scheduled maintenance ICS in asthma is poor — meta-analysis estimates cluster around 30–50% in adults, and non-adherence is strongly associated with severe exacerbations Engelkes et al. 2015. The patient psychology is intuitive: the SABA produces an immediate felt effect (bronchodilation within minutes); the ICS does not (the felt effect is the absence of attacks weeks later). The reward signal therefore points at the wrong inhaler. AIR/MART partially solves this by collapsing both inhalers into one — every reliever use is also a controller dose, so adherence to scheduling matters less. But the regimen still fails when: (a) patients revert to a stockpiled SABA inhaler at home; (b) inhaler technique is poor (a perpetual problem with metered-dose inhalers; spacers and dry-powder devices help); (c) MART patients escalate the as-needed component without seeking review when daily use rises persistently above ~4 puffs.

Practicalities

Cost: budesonide–formoterol is on the WHO Essential Medicines List and generic in most jurisdictions; an annual supply costs roughly $50–$300/year with insurance, more without. The single-inhaler simplification reduces device count and prescription complexity. Implementation barrier: in the US, the 2020 NAEPP guideline (Expert Panel Report 4) recommended SMART (the US name for MART) but stopped short of the full GINA Track 1 endorsement for AIR in mild asthma; uptake among primary care physicians has lagged. The behavioural pivot the regimen asks of patients — throw away the blue inhaler — is non-trivial.

History

The original MART/SMART concept (Single inhaler Maintenance And Reliever Therapy) emerged in early-2000s European trials of budesonide–formoterol; by mid-decade Cochrane and meta-analytic evidence supported it in moderate-to-severe asthma. The shift to as-needed-only ICS-formoterol in mild asthma was the 2018 SYGMA inflection: prior to that, mild asthma was treated with as-needed SABA alone by clinical convention, on the implicit theory that mild disease didn't warrant maintenance steroid. GINA's 2019 strategy document declared this convention obsolete and replaced it with Track 1 — a discontinuous, not incremental, revision Reddel et al. 2019.

Stakes

Untreated airway inflammation in asthma is not benign. The Sullivan analysis of insurance claims found that even moderate cumulative oral corticosteroid exposure — four lifetime OCS courses, the kind a poorly-controlled asthma patient accumulates in a few years — is associated with substantially increased risk of osteoporosis (HR ~1.2), type 2 diabetes (HR ~1.3), cataract, weight gain, hypertension, and pneumonia Sullivan et al. 2018. SABA-dominant regimens drive exacerbations; exacerbations drive OCS bursts; OCS bursts compound over decades. The mortality endpoint, while rare, is real: ~250,000 global asthma deaths annually, disproportionately occurring in SABA-reliant patients with under-treated inflammation Nwaru et al. 2020.

Payoff

Across the four pivotal AIR-pathway trials, the consistent felt-experience signal is reduced reliever use, fewer night-time awakenings, fewer "asthma weeks" per year, and fewer prednisone courses. Quality-of-life measures (ACQ-5, AQLQ) improve modestly but consistently; the bigger effect is on the tail risk — exacerbations halved relative to SABA-only baseline. For the MART user with moderate disease, the gain compounds: a typical pre-MART patient might experience 1–2 exacerbations and 1+ ED visit per year; on MART that drops by roughly a third with similar daily symptom control Sobieraj et al. 2018.

Alternatives

Track 2 in the GINA strategy — maintenance ICS with as-needed SABA — remains acceptable when ICS-formoterol is unavailable, unaffordable, or when a patient is already well-controlled on the older regimen and changing isn't worth the friction. For severe Step 5 asthma, biologic add-ons (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) target specific inflammatory pathways and are layered on top of MART, not substituted for it. Allergen immunotherapy is an adjunct in allergic phenotypes. Bronchial thermoplasty is a procedural alternative reserved for refractory disease GINA 2024.

Audience

Adolescents and adults (≥12 years) are the GINA Track 1 target population. Children 6–11 have a separate, more conservative pathway. Pregnant women: same recommendation as non-pregnant adults — controlled asthma matters more than minimising steroid exposure. Elderly: same regimen, with attention to inhaler technique and comorbid cardiac disease. SABA-only treatment is no longer recommended at any age in adolescents/adults Reddel et al. 2019.

Credibility range

The optimist case

AIR/MART is one of the cleaner wins of 21st-century pulmonology. Five large, independent, well-powered RCTs (SYGMA 1, SYGMA 2, Novel START, PRACTICAL, the older SMART trials feeding into the Cochrane review) converge on the same direction of effect for severe exacerbations: roughly halved versus SABA-only in mild asthma, roughly one-third reduced versus fixed-dose ICS-LABA+SABA in moderate-severe. The mechanism is biologically tight (anti-inflammatory dose coupled to inflammation flare moment), the comparators are realistic (the trials replicate actual clinical practice, not idealised maintenance compliance), and the harm story for the SABA-only comparator is independently confirmed in large cohort data spanning three decades Spitzer et al. 1992 Nwaru et al. 2020. Total inhaled steroid exposure goes down, not up — the regimen is therefore plausibly safer than maintenance-ICS approaches as well. Guideline endorsement (GINA) is now strong and broad. This is settled science to a degree rare in chronic disease management.

The skeptic case

Several real reservations. (1) AstraZeneca holds the patent on Symbicort (budesonide–formoterol) and has been the dominant commercial sponsor of the AIR-pathway trial programme — most pivotal trials were AZ-funded, and the comparator design (open-label in PRACTICAL and Novel START, fixed-dose in SYGMA) was favourable. The independent NZ trials replicate the result, mitigating but not eliminating the concern. (2) The exacerbation reduction in mild asthma, while statistically robust, is from an already-low baseline; absolute risk reductions are smaller than the relative ratios suggest (Novel START: 9 fewer severe exacerbations per 100 patient-years, not 50). (3) Real-world adherence to MART's maintenance component appears lower than in trials, and the as-needed-only AIR pathway introduces a different failure mode — under-treatment in patients who symptomatically downplay disease severity. (4) GINA Track 1 has been adopted globally faster than the US NAEPP guideline; some critics argue the evidence for AIR in mild asthma is strong, while the evidence-base-to-recommendation translation in MART for moderate-severe is more conservative than presented. (5) The behavioural pivot of withdrawing the salbutamol inhaler is an under-studied implementation hazard; patients who feel an attack coming may distrust the combination inhaler and seek out a SABA from outside the prescription.

Author's call

The pathway is genuinely high-evidence, high-effect, and the right default for adolescents and adults with asthma. The commercial sponsorship deserves disclosure but does not undermine the conclusion; the New Zealand replications and the independent SABINA cohort data anchor the findings on different funding sources. Implementation hurdles (clinician inertia, US guideline lag, behavioural attachment to SABA) are the dominant risk to realised benefit, not evidence-quality. Treat AIR/MART as the standard, treat the patient's individual transition off SABA as a real conversation rather than a prescription edit.

Stakeholder and incentive map

• AstraZeneca — patent holder for budesonide–formoterol (Symbicort) and primary trial sponsor for SYGMA, Novel START, PRACTICAL. Commercial interest aligns with the GINA Track 1 recommendation. Mitigation: independent replications exist; budesonide–formoterol is now generic in many jurisdictions, reducing remaining commercial leverage.
• GINA (Global Initiative for Asthma) — international guidelines body, jointly sponsored by WHO and NHLBI heritage; the 2019 strategy revision was its largest in 30 years. Reputational stake in the regimen's success.
• NAEPP (US) and NICE/BTS (UK) — national guideline bodies. NAEPP 2020 endorsed SMART (MART) but stopped short of GINA Track 1 for mild asthma; the divergence has been a point of professional debate. NICE/BTS aligned more closely with GINA.
• SABA manufacturers — salbutamol/albuterol generics are commoditised; little remaining commercial incentive to defend SABA-only, but clinical inertia among prescribers and patient familiarity remain strong forces.
• Primary care clinicians — gatekeeper to the regimen change. Switching costs (education, prescription pad changes, patient counselling time) are real and unreimbursed.
• Patients — psychological attachment to the blue inhaler is strong. The reliever is the "rescue" — a felt safety object. Asking a patient to throw it away requires trust-building.

Population variability

Effect direction is consistent across age (12+), gender, asthma severity (mild through severe), and ethnicity in pooled trial data. The magnitude varies: highest absolute benefit accrues to patients with high baseline SABA use (≥3 canisters/year), frequent symptoms, or a recent exacerbation history. Patients already well-controlled on maintenance ICS+SABA gain less in absolute terms; the case for switching them is weaker. Pregnant women: explicitly studied as safe and recommended GINA 2024. Children 6–11: GINA recommends a separate pathway with lower-dose ICS-formoterol or maintenance ICS, not the full Track 1 approach — the evidence base is thinner in this age band. Asthma–COPD overlap patients: regimens differ; MART concept holds but dosing changes. Aspirin-exacerbated respiratory disease (AERD) and eosinophilic phenotypes respond, but may need biologic add-ons.

Knowledge gaps

• Long-term (10+ year) outcomes of AIR vs maintenance ICS — most trials are 52 weeks. Total cumulative ICS dose is lower with AIR, theoretically reducing long-term steroid side effects (bone density, ocular, growth in adolescents), but this hasn't been tracked at scale.
• Real-world adherence to MART's maintenance component outside trial settings — early observational data suggests it's lower than trial estimates, but how much that erodes the exacerbation reduction is unclear.
• Optimal upper limit on as-needed doses — current ceilings (~8–12/day) are pragmatic rather than evidence-based; the dose-response of formoterol toxicity above that range is under-characterised.
• Phenotype-targeted refinements — eosinophilic, T2-low, allergic, and neutrophilic phenotypes may respond differently; the trial populations are largely mixed.
• Implementation science — the gap between guideline and practice (clinician uptake, patient acceptance of SABA withdrawal) is the dominant determinant of realised population benefit and is poorly studied.

Scope calls and rationale a reviewer can't infer from the prose:

• Audience. Written for an adult or adolescent reader with an existing asthma diagnosis, not for general health-literate readers. The 12-and-under pathway is mentioned in the contraindications callout as a flag, not covered in detail — separate-entry candidate.
• SABA mortality framing. Included because it's load-bearing for the "blue puffer is dangerous" reframe, but kept proportionate — the absolute death rate is low and most heavy users will not die of asthma. Stakes and misconceptions sections both name the dose-response without dramatising.
• Action = decide, not do. This is a prescription pathway; the reader's action is talking to a clinician about switching, not buying something. Cadence = daily because MART (the larger user group) is daily and AIR is sustained, even if the actuations on AIR are as-needed.
• Contraindications field left empty. No closed-vocabulary token genuinely makes AIR/MART unsafe — pregnancy is explicitly recommended, cardiac caution is real but rarely outweighs the asthma indication. The cautions belong in the article's warning callout, not as a contraindication tag that would gate the entry away from groups who should still be considering it.
• Brand and drug naming. Used budesonide–formoterol as the canonical compound (Symbicort being the originator); beclomethasone–formoterol mentioned where relevant. Stayed away from the trade name in the body since generic versions dominate most jurisdictions now.
• Pediatric asthma management — separate-entry candidate. Step-2-and-below children have a distinct pathway (no AIR; lower-dose maintenance ICS preferred) and a different evidence base.
• Severe-asthma biologics (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) — pointed to in out-of-scope but each warrants its own entry; they sit on top of MART rather than substituting for it.
• SABA-only as a separate harm entry? Considered. Rejected: the SABA harm story is the natural foil for this entry and reads better here than in isolation. A standalone SABA overuse entry would mostly recapitulate the stakes and evidence sections.
• Future links. When the following entries land, this one should cross-link: mouth-tape at night, indoor allergen reduction, smoking cessation, severe-asthma biologics, aerobic conditioning for chronic lung disease.
• Rating difficulty: longevity = 3. The mortality signal is dose-dependent and real but the absolute effect for the average adult with mild asthma is small. Scored against the substance's effect in its target population (asthmatics with meaningful SABA reliance), not against a general-population baseline. A lower score would under-weight the patients who most need this regimen.
• Rating difficulty: effort_burden = 2. AIR users have effort closer to 1; MART users closer to 2–3. Averaged for the entry's holistic score.
• Controversy = 2. GINA vs US NAEPP divergence is the largest contested point; AstraZeneca's sponsorship of pivotal trials is the secondary one. Both real, both mitigated by independent NZ replications and generic availability.